NFCR-backed technology receives FDA's assent for lymphoma clinical trials

(National Foundation for Cancer Research) National Foundation for Cancer Research-backed drug and drug delivery technology receives assent from US Food and Drug Administration for T-cell non-Hodgkin's lymphoma clinical trials. The milestone represents another example of promising translational cancer research supported by the organization and its donors.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news